HBM Healthcare Investments
HBM Healthcare Investments is a publicly listed investment company with a globally diversified portfolio of private and publicly traded companies in the healthcare sector. The firm focuses on promising companies in human medicine, biotechnology, medical technology, and diagnostics, supporting them strategically to enhance their growth and market presence. HBM Healthcare Investments is listed on the SIX Swiss Exchange under the symbol HBMN.
HBM Healthcare Investments
Bundesplatz 1, 6300 Zug, Schweiz
Portfolio
Neurelis licenses, develops, and commercializes product candidates for the broader central nervous system (CNS), including epilepsy and psychiatry.
#Central Nervous System (CNS)
Swixx Biopharma expects a revenue jump to over EUR 700 million for the fiscal year 2022, resulting in a dividend income of CHF 10 million for HBM Healthcare Investments.
#Pharmaceutical Distribution
Fangzhou plans an IPO on the Hong Kong Stock Exchange, with a prospectus filed in November.
#Healthcare Platform
Viela Bio is a biotechnology company focused on treatments for severe inflammation and autoimmune diseases. HBM Healthcare Investments led a USD 75 million private placement with a USD 20 million investment.
#Biotechnology
1000Farmacie is the leading Italian e-pharmacy and digital healthcare platform with a vision to improve healthcare services and medicine delivery to customers and patients.
#Healthcare IT